Abstract

Sézary syndrome (SS) is a heterogeneous leukemic subtype of cutaneous T-cell lymphoma (CTCL) with generalized erythroderma, lymphadenopathy, and a poor prognosis. Advanced disease is invariably associated with severe immune dysregulation and the majority of patients die from infectious complications caused by microorganisms such as, Staphylococcus aureus, rather than from the lymphoma per se. Here, we examined if staphylococcal enterotoxins (SE) may shape the phenotype of malignant SS cells, including expression of the regulatory T-cell-associated marker FOXP3. Our studies with primary and cultured malignant cells show that SE induce expression of FOXP3 in malignant cells when exposed to nonmalignant cells. Mutations in the MHC class II binding domain of SE-A (SEA) largely block the effect indicating that the response relies at least in part on the MHC class II-mediated antigen presentation. Transwell experiments show that the effect is induced by soluble factors, partly blocked by anti-IL-2 antibody, and depends on STAT5 activation in malignant cells. Collectively, these findings show that SE stimulate nonmalignant cells to induce FOXP3 expression in malignant cells. Thus, differences in exposure to environmental factors, such as bacterial toxins may explain the heterogeneous FOXP3 expression in malignant cells in SS.

Details

Title
Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndrome
Author
Willerslev-Olsen, Andreas 1 ; Buus, Terkild B 1   VIAFID ORCID Logo  ; Nastasi, Claudia 1 ; Blümel Edda 1 ; Gluud, Maria 1 ; Bonefeld, Charlotte M 1   VIAFID ORCID Logo  ; Geisler Carsten 1   VIAFID ORCID Logo  ; Lindahl, Lise M 2 ; Vermeer Maarten 3 ; Wasik, Mariusz A 4 ; Iversen, Lars 2 ; Becker, Jürgen C 5 ; Andersen, Mads Hald 6 ; Gjerdrum Lise M R 7 ; Litvinov, Ivan V 8   VIAFID ORCID Logo  ; Litman, Thomas 1   VIAFID ORCID Logo  ; Krejsgaard Thorbjørn 1 ; Woetmann Anders 1   VIAFID ORCID Logo  ; Ødum Niels 1 

 University of Copenhagen, Department of Immunology and Microbiology; LEO Foundation Skin Immunology Research Center, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X) 
 Aarhus University Hospital, Department of Dermatology, Aarhus, Denmark (GRID:grid.154185.c) (ISNI:0000 0004 0512 597X) 
 Leiden University Medical Center, Department of Dermatology, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978) 
 University of Pennsylvania, Department of Pathology and Laboratory Medicine, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972) 
 German Cancer Consortium (DKTK), University Hospital of Essen, Department of Translational Skin Cancer Research, Essen, Germany (GRID:grid.410718.b) (ISNI:0000 0001 0262 7331); Deutsches Krebsforschungsinstitut (DKFZ), Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584) 
 Herlev Hospital, University of Copenhagen, Center for Cancer Immune Therapy, Department of Hematology, Herlev, Denmark (GRID:grid.411900.d) (ISNI:0000 0004 0646 8325) 
 Zealand University Hospital, Department of Pathology, Roskilde, Denmark (GRID:grid.476266.7) 
 McGill University Health Centre, Division of Dermatology, Montreal, Canada (GRID:grid.63984.30) (ISNI:0000 0000 9064 4811) 
Publication year
2020
Publication date
May 2020
Publisher
Springer Nature B.V.
e-ISSN
20445385
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2403003029
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.